Radium-223 Improves Survival, Delays Time to Skeletal-Related Events in Castration-Resistant Prostate Cancer
The novel alpha-pharmaceutical radium-223 chloride may provide a new standard of care for the treatment of patients with castration-resistant prostate cancer (CRPC) with bone metastases.